University of North Carolina, Chapel Hill: Schizophrenia trials

The registry lists 23 Schizophrenia studies with University of North Carolina, Chapel Hill as lead sponsor. 0 are open to participants now and 13 have results posted.

Phase 1 3Phase 2 2Phase 4 2No phase 16(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Horyzons: Implementation and Integration in Clinical PracticeTerminatedNCT06002958Not applicableResults posted
• Horyzons: Implementation in Clinical PracticeCompletedNCT04673851Not applicableResults posted
• Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life Randomized Control TrialCompletedNCT04173572Not applicableResults posted
• Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance LifeCompletedNCT03757988Not applicableResults posted
• Targeting Auditory Hallucinations With Alternating Current StimulationCompletedNCT03221270Not applicableResults posted
• Targeting Stress Reactivity in Schizophrenia: Integrated Coping Awareness TherapyCompletedNCT03067311Not applicableResults posted
• MEtformin and Lorcaserin for WeighT Loss in SchizophreniaTerminatedNCT02796144Phase 4Results posted
• STimulation to Improve Auditory haLLucinationsCompletedNCT02360228Not applicableResults posted
• Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in SchizophreniaCompletedNCT01963676Not applicableResults posted
• Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and AdolescentsCompletedNCT01731119Phase 2Results posted
• Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) StudyCompletedNCT01269710Results posted
• Oxytocin Treatment of SchizophreniaCompletedNCT01028677Not applicableResults posted
• Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)CompletedNCT00053703Phase 4Results posted
• Integrated Coping and Awareness TrainingCompletedNCT02400502Not applicable
• Oxytocin Treatment of Social Cognitive and Functional Deficits in SchizophreniaCompletedNCT01394471Phase 1
• Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRICompletedNCT01234454Not applicable
• Ziprasidone in Early Onset Schizophrenia Spectrum DisordersCompletedNCT01006551Phase 2
• Improving Representative Payeeship for People With Psychiatric Disabilities and Their FamiliesCompletedNCT00924976Not applicable
• Prospective Studies of the Pathogenesis of SchizophreniaCompletedNCT00877552
• Social Cognition and Interaction Training for Improving Social Functioning in People With SchizophreniaCompletedNCT00601224Phase 1
• Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and QuetiapineCompletedNCT00312598
• Graduated Recovery Intervention Program for Enhancing Treatment for First-Episode PsychosisCompletedNCT00307216Not applicable
• Study of Amantadine for Weight Stabilization During Olanzapine TreatmentCompletedNCT00287352Phase 1